International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Scholarly Publisher
RS Global Sp. z O.O.
ISNI: 0000 0004 8495 2390

Dolna 17, Warsaw,
Poland 00-773
+48 226 0 227 03
editorial_office@rsglobal.pl

ARTICLE TITLE	THE ROLE OF ARTIFICIAL INTELLIGENCE IN AUTOMATED DETECTION OF DIABETIC RETINOPATHY: CLINICAL AND PUBLIC HEALTH PERSPECTIVES
ARTICLE INFO	Aneta Rasińska, Paulina Bala, Justyna Matusik, Piotr Rzyczniok, Mateusz Kopczyński, Justyna Jachimczak. (2025) The Role of Artificial Intelligence in Automated Detection of Diabetic Retinopathy: Clinical and Public Health Perspectives. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3533
DOI	https://doi.org/10.31435/ijitss.3(47).2025.3533
RECEIVED	23 June 2025
ACCEPTED	01 August 2025
PUBLISHED	07 August 2025
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

THE ROLE OF ARTIFICIAL INTELLIGENCE IN AUTOMATED DETECTION OF DIABETIC RETINOPATHY: CLINICAL AND PUBLIC HEALTH PERSPECTIVES

Aneta Rasińska *(Corresponding Author, Email: ane.rasinska@gmail.com)*
Municipal Hospital No. 4 in Gliwice Ltd. Zygmunta Starego 20, 44-100, Poland
ORCID ID: 0009-0007-2872-8000

Paulina Bala
Our Lady of Perpetual Help Hospital in Wołomin, 05-200 Wołomin, ul. Gdyńska 1/3, Poland
ORCID ID: 0009-0007-0604-8549

Justyna Matusik
Academy of Silesia in Katowice, 40-555 Katowice, ul. Rolna 43, Poland
ORCID ID: 0009-0009-7907-9690

Piotr Rzyczniok
Private Healthcare Institution ProCordi Ltd., 44-335 Jastrzębie Zdrój, ul. Wyspiańskiego 8, Poland
ORCID ID: 0009-0004-5899-2345

Mateusz Kopczyński
Municipal Hospital Complex in Częstochowa, Częstochowa 42-200, ul. Mirowska 15, Poland
ORCID ID: 0009-0009-6592-3061

Justyna Jachimczak
Our Lady of Perpetual Help Hospital in Wołomin, 05-200 Wołomin, ul. Gdyńska 1/3, Poland
ORCID ID: 0009-0005-7614-9500

ABSTRACT

Introduction and Objective: Diabetic retinopathy (DR) is a serious microvascular complication of diabetes and a leading cause of preventable blindness worldwide. With the global rise in diabetes prevalence, especially in low- and middle-income countries, early detection and timely treatment of DR have become critical. This paper reviews the evolving role of artificial intelligence (AI) in the automated detection of DR, evaluating its clinical effectiveness, implementation challenges, and potential impact on global preventive eye care.
Review Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science databases to identify relevant literature published between 2016 and 2021. Search terms included combinations of "diabetic retinopathy," "artificial intelligence," "deep learning," and "automated detection." Articles were selected based on their relevance and contribution to advances, clinical applications, and challenges in AI-based DR screening.
State of Knowledge: Deep learning algorithms have demonstrated high accuracy in retinal image analysis, often matching expert ophthalmologists in detecting referable DR. AI enables scalable, rapid, and accessible screening, especially in regions with limited specialist availability. Challenges include data quality and diversity, algorithm transparency, patient privacy, clinical acceptance, and evolving regulatory frameworks.
Conclusion: AI represents a transformative opportunity to improve early diagnosis and management of diabetic retinopathy globally. To fully realize its benefits, ethical, technical, and regulatory issues must be addressed to ensure safe, effective, and equitable integration of AI into healthcare systems worldwide.

KEYWORDS

Diabetic Retinopathy (DR), Artificial Intelligence (AI), Deep Learning, Automated Screening, Retinal Image Analysis, Teleophthalmology

CITATION

Aneta Rasińska, Paulina Bala, Justyna Matusik, Piotr Rzyczniok, Mateusz Kopczyński, Justyna Jachimczak. (2025) The Role of Artificial Intelligence in Automated Detection of Diabetic Retinopathy: Clinical and Public Health Perspectives. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3533

Introduction.

Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and represents one of the most common causes of vision impairment and preventable blindness globally (Yau et al., 2012). As the prevalence of diabetes continues to rise worldwide, particularly in low- and middle-income countries, the burden of DR is expected to increase substantially in the coming decades (International Diabetes Federation, 2021). Early detection and timely treatment of DR are critical in preventing the progression to advanced stages that can lead to severe visual impairment or blindness (Cheung, Mitchell, & Wong, 2010). However, the asymptomatic nature of early DR often results in delayed diagnosis, with many patients only seeking care once significant vision loss has occurred (Scanlon, 2017).

Regular retinal screening is therefore essential for individuals with diabetes to identify DR at an early, treatable stage. Unfortunately, access to ophthalmic screening services is limited in many regions due to shortages of eye care professionals, high costs, and logistical challenges, particularly in rural and underserved populations (Pascolini & Mariotti, 2012). These barriers contribute to disparities in eye health outcomes and underscore the need for scalable, affordable, and accessible screening solutions.

Recent advancements in artificial intelligence (AI), especially deep learning techniques, have demonstrated significant potential in automating the analysis of retinal images for the detection of DR (Gulshan et al., 2016). AI-based diagnostic tools can analyze large volumes of fundus photographs rapidly and with accuracy comparable to that of trained ophthalmologists (Abràmoff et al., 2018). Such technology offers a promising approach to overcoming current limitations by enabling earlier detection, improving screening coverage, and reducing the burden on healthcare systems.

Beyond accuracy, AI-driven screening tools have the advantage of being deployable in primary care settings and even remote areas, facilitating telemedicine initiatives and bringing eye care closer to patients who otherwise lack access (Ting et al., 2019). Nevertheless, the integration of AI into clinical practice raises important questions about ethical considerations, data privacy, acceptance by healthcare providers and patients, and regulatory frameworks (Beede et al., 2020).

This article explores the evolving role of AI in the automated detection of diabetic retinopathy, evaluating its clinical effectiveness, implementation challenges, and potential to transform preventive eye care on a global scale. Through reviewing current technologies, real-world applications, and policy implications, the paper aims to provide a comprehensive understanding of AI’s place at the forefront of innovation in ophthalmology and public health.

Methodology

This narrative review was conducted by searching key scientific databases, including PubMed, Scopus, and Web of Science, for relevant literature published between 2016 and 2021. The search strategy involved combining terms related to diabetic retinopathy and artificial intelligence, such as “diabetic retinopathy,” “AI,” “deep learning,” and “automated detection.” Unlike a systematic review, the selection of studies was guided by their relevance and contribution to the topic rather than strict inclusion criteria. Emphasis was placed on highlighting significant advancements, clinical applications, and challenges in the use of AI for diabetic retinopathy screening and diagnosis.

Clinical and Public Health Perspective

DR is a progressive microvascular complication resulting from chronic hyperglycemia, which damages the small blood vessels of the retina (Cheung, Mitchell, & Wong, 2010). DR typically evolves through several stages, beginning with mild non-proliferative changes such as microaneurysms and hemorrhages, progressing to proliferative retinopathy characterized by neovascularization, and potentially culminating in macular edema and vision loss if left untreated (Aiello et al., 1998). The asymptomatic nature of early-stage DR presents a significant challenge, as patients often remain unaware of retinal damage until substantial and irreversible visual impairment occurs (Scanlon, 2017).

Globally, diabetic retinopathy affects approximately one-third of individuals with diabetes, making it a major public health concern (Yau et al., 2012). The risk of developing DR correlates strongly with the duration of diabetes and poor glycemic control, but other factors such as hypertension, dyslipidemia, and genetic predisposition also contribute (Stitt et al., 2016). Early detection through regular retinal screening and timely intervention can prevent up to 95% of vision loss related to DR (Wong et al., 2018).

Standard diagnostic methods for DR include fundus photography and optical coherence tomography (OCT), which require specialized equipment and trained ophthalmologists to interpret results (Abràmoff et al., 2018). In many low-resource settings and rural areas, however, a shortage of specialists and limited access to diagnostic infrastructure hampers regular screening efforts (Pascolini & Mariotti, 2012). This disparity contributes to inequities in health outcomes, with vulnerable populations facing higher risks of undiagnosed and untreated DR (Zhao et al., 2019).

From a public health perspective, establishing effective and scalable screening programs is critical to reducing the global burden of diabetic blindness (Scanlon, 2017). Screening programs, such as those implemented in the United Kingdom and Singapore, have demonstrated success in increasing early detection and decreasing rates of severe visual impairment (Yau et al., 2012; Tan et al., 2017). Nonetheless, challenges remain in expanding these programs to areas with fewer resources and in integrating screening with broader diabetes care.

Innovative solutions are needed to overcome these barriers, improve access to screening, and optimize resource allocation. In this context, artificial intelligence-driven automated detection systems offer a promising path toward more inclusive and efficient public health strategies for DR prevention.

Artificial Intelligence in Retinal Image Analysis

AI, particularly through advancements in deep learning and convolutional neural networks (CNNs), has brought a paradigm shift in the analysis of medical images, with DR being a key area of application. The retina's distinct microvascular structure and the widespread availability of fundus photography have facilitated the creation of large datasets necessary for training AI models capable of recognizing subtle retinal lesions associated with DR (Gulshan et al., 2016). These lesions include microaneurysms, intraretinal hemorrhages, hard exudates, cotton wool spots, and neovascularization—each indicative of specific stages in the progression of DR.

Deep learning algorithms are trained on thousands to millions of labeled retinal images, learning hierarchical feature representations that enable the automated classification of DR severity with impressive accuracy (Gargeya & Leng, 2017). For example, the landmark study by Gulshan et al. (2016) demonstrated that a deep learning system achieved sensitivity and specificity exceeding 90% in detecting referable DR, rivalling the performance of expert ophthalmologists. Subsequent studies have further refined these algorithms, incorporating multimodal imaging data, such as optical coherence tomography (OCT), to improve the detection of diabetic macular edema (Abràmoff et al., 2018).

Beyond diagnostic performance, AI-powered retinal image analysis systems provide several practical benefits. They enable rapid processing of large numbers of images, which is particularly valuable in large-scale screening programs aiming to cover entire diabetic populations. This scalability can alleviate bottlenecks in healthcare systems with limited ophthalmic workforce capacity (Ting et al., 2019). Additionally, AI tools facilitate point-of-care screening in primary care settings, reducing the need for patient referrals and enabling earlier intervention (Li et al., 2020).

Importantly, AI-driven retinal screening is instrumental in teleophthalmology programs, which use digital fundus photography and remote interpretation to extend eye care access to rural and underserved regions (Bellemo et al., 2019). This approach reduces geographic and economic barriers that traditionally limit screening uptake. When integrated with AI, teleophthalmology gains increased efficiency by automating the initial grading step, reserving human expert review only for ambiguous or high-risk cases.

Nevertheless, several challenges limit the widespread adoption and optimization of AI in DR detection. First, AI models require extensive, high-quality, and diverse datasets to generalize effectively across different populations, camera types, and image qualities (Mookiah et al., 2021). Many existing datasets predominantly represent populations from high-income countries, raising concerns about algorithmic bias and reduced accuracy in ethnically or regionally distinct groups (Beede et al., 2020).

Second, the "black box" nature of deep learning poses transparency issues. Clinicians and regulators often demand explainability to understand how AI systems arrive at diagnostic conclusions, crucial for clinical acceptance and patient trust (Samek et al., 2017). Emerging techniques in explainable AI (XAI) are being developed to highlight image regions influencing model decisions, but these are still in early stages of clinical validation.

Third, ethical considerations surrounding data privacy and informed consent are paramount. The use of patient retinal images, often combined with sensitive health information, requires stringent data protection measures in line with regulations such as GDPR and HIPAA (Char et al., 2018). Additionally, ensuring equitable access to AI technologies is critical to avoid exacerbating existing health disparities, especially in low-resource settings where infrastructure to support AI may be lacking (Rajkomar et al., 2018).

Finally, regulatory frameworks for AI in medical devices are evolving but remain inconsistent across regions. The approval process must balance innovation speed with robust validation to guarantee patient safety and efficacy (Lee et al., 2019). Continuous post-market surveillance is also needed to monitor AI system performance in real-world settings and address potential degradations or unintended consequences.

In conclusion, AI-powered retinal image analysis represents a transformative and promising approach to diabetic retinopathy screening. Its ability to deliver accurate, scalable, and accessible diagnostics can significantly improve early detection and management of DR worldwide. However, maximizing its benefits requires addressing data diversity, transparency, ethical concerns, and regulatory challenges through multidisciplinary collaboration among technologists, clinicians, ethicists, and policymakers.

Benefits of AI-Based Diabetic Retinopathy Screening

AI-based screening for DR offers numerous benefits that address current limitations in diabetic eye care and present opportunities for improved public health outcomes.

Increased Accessibility and Scalability

AI systems enable automated and rapid analysis of retinal images, facilitating large-scale screening programs that would be challenging with human graders alone. This scalability is crucial given the rising global prevalence of diabetes and the consequent burden of DR (International Diabetes Federation, 2021). AI-powered screening can be deployed in primary care clinics, community health centers, and remote areas lacking ophthalmologists, thus overcoming geographic and workforce shortages (Ting et al., 2019). This decentralization helps increase screening coverage and early detection rates, especially in underserved populations.

Improved Screening Accuracy and Consistency

Deep learning algorithms have demonstrated high sensitivity and specificity in detecting referable diabetic retinopathy, often matching or surpassing the diagnostic performance of experienced ophthalmologists (Gulshan et al., 2016). AI systems reduce inter- and intra-observer variability, ensuring consistent grading quality across different settings and timepoints (Abràmoff et al., 2018). This reliability is essential for longitudinal monitoring of disease progression and treatment outcomes.

Cost-Effectiveness and Efficiency

By automating the initial screening step, AI reduces the need for extensive specialist involvement in grading every image, decreasing costs and wait times (Li et al., 2020). This efficiency allows healthcare systems to allocate ophthalmology resources to patients who require intervention rather than routine screening. Additionally, faster screening turnaround facilitates timely referrals, reducing the risk of vision loss from delayed diagnosis.

Facilitation of Teleophthalmology and Remote Care

AI integration with teleophthalmology platforms enhances remote eye care services by automating image interpretation and triage. Patients in rural or resource-limited areas can have retinal images captured locally and analyzed by AI, with only abnormal or uncertain cases forwarded to specialists (Bellemo et al., 2019). This model expands access, improves convenience, and reduces patient travel and associated costs.

Empowerment of Healthcare Providers

AI tools support non-specialist healthcare providers by assisting in DR screening and enabling them to play a more active role in managing diabetic eye health. This empowerment can improve patient education, follow-up adherence, and overall disease management (Ting et al., 2019). The availability of AI feedback also aids continuous learning and confidence building among primary care staff.

Potential for Integration with Comprehensive Diabetes Care

AI-based retinal screening can be integrated into broader diabetes management platforms, linking ocular health with systemic disease parameters such as glycemic control, blood pressure, and lipid levels. This holistic approach supports personalized risk stratification, enabling tailored screening intervals and preventive strategies (Rajkomar et al., 2018).

Ethical, Technical, and Implementation Challenges

Despite the significant benefits of AI-based DR screening, there are several challenges that must be addressed to ensure the technology is used safely, effectively, and equitably.

Ethical Challenges

Patient Privacy and Data Security: AI models require large volumes of retinal images and associated patient data, raising concerns about confidentiality and data protection. Ensuring compliance with regulations such as GDPR and HIPAA is critical to protect sensitive health information (Char et al., 2018). Secure data storage, anonymization techniques, and strict access controls are necessary safeguards.

Algorithmic Bias and Fairness: AI systems trained on datasets lacking demographic diversity may underperform on underrepresented groups, perpetuating or exacerbating health disparities (Rajkomar et al., 2018). Transparency in data sources, ongoing bias assessment, and inclusive dataset development are essential to promote fairness and equity in care delivery.

Transparency and Explainability: Many AI algorithms, especially deep learning models, operate as "black boxes," making it difficult for clinicians and patients to understand the rationale behind diagnostic outputs (Samek et al., 2017). Lack of explainability can undermine trust and complicate clinical decision-making. Research into interpretable AI methods aims to provide clearer insights into model decisions.

Informed Consent and Patient Autonomy: Patients should be informed when AI tools are used in their care, including potential benefits and limitations. Maintaining patient autonomy requires clear communication and opportunities to discuss AI-assisted results with healthcare providers.

Technical Challenges

Data Quality and Generalizability: AI performance depends heavily on the quality and diversity of training data. Variability in image resolution, lighting conditions, and disease presentation can affect accuracy (Mookiah et al., 2021). Models must be validated and calibrated for specific populations and imaging devices to ensure robustness.

Integration with Clinical Workflows: Successful AI adoption requires seamless integration into existing healthcare infrastructure. Interoperability with electronic health records (EHRs), compatibility with various fundus cameras, and user-friendly interfaces for clinicians are necessary for efficient use (Ting et al., 2019).

Maintenance and Updating: AI models require continuous updating to maintain accuracy as new data and disease patterns emerge. Establishing procedures for regular retraining, monitoring performance, and addressing "model drift" is a significant technical challenge.

Implementation Challenges

Regulatory Approval and Oversight: AI-based diagnostic tools must undergo rigorous evaluation and approval by regulatory bodies such as the FDA or EMA before clinical use. Regulatory frameworks are evolving but may not yet fully address unique aspects of AI, including continuous learning and real-world performance monitoring (Lee et al., 2019).

Clinical Acceptance and Training: Healthcare providers may be hesitant to trust or rely on AI outputs without sufficient evidence and training. Building confidence through education, demonstration of clinical efficacy, and clear guidelines is essential for widespread adoption.

Cost and Infrastructure Barriers: Implementing AI screening programs requires investment in imaging devices, IT infrastructure, and training, which may be prohibitive in low-resource settings (Bellemo et al., 2019). Addressing these barriers is critical to ensuring equitable access.

Legal and Liability Issues: Determining responsibility in cases of AI-related misdiagnosis or adverse outcomes is complex. Clear policies on liability among AI developers, healthcare providers, and institutions are needed to mitigate legal risks.

Global Strategies and Practices

The global implementation of AI-based DR screening highlights diverse approaches tailored to different healthcare systems and population needs. Below are key examples from the USA, India, and the UK, illustrating both successes and lessons learned.

United States: IDx-DR System in Primary Care Clinics

IDx-DR was the first autonomous AI diagnostic system approved by the U.S. Food and Drug Administration (FDA) for detecting more than mild diabetic retinopathy without specialist oversight (Abràmoff et al., 2018). This system allows primary care providers to capture retinal images using a fundus camera, which are then automatically analyzed by the AI. Patients with positive findings are referred to ophthalmologists for confirmation and treatment.

The deployment of IDx-DR in primary care settings has increased screening rates by integrating eye exams into routine diabetes management, reducing barriers associated with specialist visits (Abràmoff et al., 2018). This model demonstrates how AI can empower non-specialist providers and improve early detection through decentralized screening.

India: Aravind Eye Care System and AI Integration

India faces a high burden of diabetic retinopathy with limited ophthalmologist availability, especially in rural areas. The Aravind Eye Care System has pioneered the use of AI-assisted screening combined with teleophthalmology to reach underserved populations (Rajalakshmi et al., 2018). Retinal images are captured at community clinics or mobile units and analyzed by AI algorithms to triage patients.

This hybrid model optimizes specialist resources by focusing attention on patients flagged by AI, enabling timely intervention and reducing unnecessary referrals. Additionally, training local healthcare workers to use AI tools has expanded capacity and community trust. The Aravind experience underscores the importance of context-specific adaptation and capacity building in low-resource settings.

United Kingdom: Google DeepMind's Research on Retinal Imaging

Google DeepMind has conducted extensive research into AI algorithms for detecting retinal diseases including diabetic retinopathy, leveraging large-scale datasets from the UK's National Health Service (NHS) (De Fauw et al., 2018). Their models not only detect DR but also other ocular conditions, highlighting AI's potential for comprehensive eye screening.

This collaboration emphasizes the value of integrating AI development within national health systems to access rich data, facilitate regulatory compliance, and pilot real-world implementation. The UK example also highlights the ethical and privacy frameworks required for handling sensitive health data at scale.

Lessons for Global Health Systems

These case studies collectively reveal key lessons for adopting AI-based DR screening worldwide:

- Tailored Integration: Successful implementation requires alignment with local healthcare infrastructure, workforce capacity, and patient population characteristics (Ting et al., 2019).
- Capacity Building: Training and empowering non-specialist healthcare workers to operate AI systems expands reach and sustainability.
- Regulatory Navigation: Early engagement with regulatory bodies ensures compliance and facilitates smoother deployment.
- Data Governance: Robust data privacy, security, and ethical frameworks build patient and provider trust.
- Resource Optimization: AI enables efficient triage, focusing specialist attention on high-risk patients and reducing unnecessary workload.
- Equity Focus: Addressing the digital divide and ensuring access in low-resource settings is essential to avoid widening disparities.

Conclusions

AI represents a transformative advancement in the early detection and management of DR, a leading cause of preventable blindness worldwide. The integration of AI-based screening tools into healthcare systems offers significant benefits, including increased accessibility, enhanced diagnostic accuracy, improved efficiency, and expanded reach to underserved populations. Case studies from the United States, India, and the United Kingdom demonstrate the practical feasibility and positive impact of AI in diverse clinical and resource settings.

However, realizing the full potential of AI in DR screening requires addressing critical ethical, technical, and implementation challenges. Ensuring patient privacy, minimizing algorithmic bias, and fostering transparency are essential for maintaining trust and equity in care. Technical challenges such as data quality, integration with clinical workflows, and continuous model updates must be managed carefully to sustain performance. Furthermore, successful deployment depends on regulatory approval, provider acceptance, adequate infrastructure, and clear legal frameworks.

Future efforts should focus on developing explainable AI models, expanding inclusive datasets, and creating scalable, cost-effective solutions adaptable to various healthcare contexts. Collaborative partnerships among clinicians, technologists, policymakers, and patient communities will be vital to navigate complexities and optimize AI-driven DR screening.

In summary, AI holds promise as a new frontier in preventive eye care, with the potential to reduce the global burden of diabetic retinopathy and preserve vision for millions. Thoughtful integration and ongoing evaluation will be key to harnessing this technology responsibly and equitably for improved public health outcomes.

Disclosure: Authors do not report any disclosures.

Authors' contributions:
Conceptualization: P. Bala, A. Rasińska;
Methodology: P. Rzyczniok, M. Kopczyński;
Software: n/a; check: P. Bala, J. Jachimczak;
Formal analysis: M. Matusik;
Investigation: A. Rasińska;
Resources: J. Jachimczak, M. Kopczyński, A. Rasińska
Data curation: M. Kopczyński, J. Jachimczak;
Writing -rough preparation: A. Rasińska, P. Bala;
Writing -review and editing: P. Rzyczniok, J. Matusik;
Visualization, P. Rzyczniok, M. Kopczyński;
Supervision: M. Matusik;
Project administration: A. Rasińska;
Receiving funding: n/a.

All authors have read and agreed with the published version of the manuscript.

Funding statement: This research received no external funding.
Institutional Review: Board Statement Not applicable.
Informed Consent Statement: Not applicable.
Data availability statement: Not applicable.
Acknowledgments: The authors declare that there are no acknowledgments for this study.
Conflict of Interest Statement: The authors declare no conflict of interest.

REFERENCES

1. Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *NPJ Digital Medicine, 1*(1), 39. https://doi.org/10.1038/s41746-018-0040-6
2. Aiello, L. P., Cahill, M. T., & Wong, J. S. (1998). Systemic considerations in the management of diabetic retinopathy. *American Journal of Ophthalmology, 126*(4), 482-497. https://doi.org/10.1016/S0002-9394(98)00130-4
3. Beede, E., Baylor, E., Hersch, F., Iurchenko, A., Wilcox, L., Ruamviboonsuk, P., & Vardoulakis, L. M. (2020). Human-centered evaluation of a deep learning system deployed in clinics for the detection of diabetic retinopathy. *Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems*, 1–12. https://doi.org/10.1145/3313831.3376718
4. Bellemo, V., Lim, Z. W., Rim, T. H., Tan, G. S. W., Lee, S. Y., Yip, M., ... & Wong, T. Y. (2019). Artificial intelligence screening for diabetic retinopathy: the real-world implementation of teleophthalmology and AI. *British Journal of Ophthalmology, 103*(2), 167-175. https://doi.org/10.1136/bjophthalmol-2018-312808
5. Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care — addressing ethical challenges. *The New England Journal of Medicine, 378*(11), 981-983. https://doi.org/10.1056/NEJMp1714229
6. Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. *The Lancet, 376*(9735), 124-136. https://doi.org/10.1016/S0140-6736(09)62124-3
7. De Fauw, J., Ledsam, J. R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell, S., ... & Ronneberger, O. (2018). Clinically applicable deep learning for diagnosis and referral in retinal disease. *Nature Medicine, 24*(9), 1342-1350. https://doi.org/10.1038/s41591-018-0107-6
8. Gargeya, R., & Leng, T. (2017). Automated identification of diabetic retinopathy using deep learning. *Ophthalmology, 124*(7), 962-969. https://doi.org/10.1016/j.ophtha.2017.02.008
9. Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., … Webster, D. R. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA, 316*(22), 2402-2410. https://doi.org/10.1001/jama.2016.17216
10. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://diabetesatlas.org/
11. Lee, C. S., Tyring, A. J., Deruyter, N. P., Wu, Y., Rokem, A., & Lee, A. Y. (2019). Deep learning is effective for classifying normal versus age-related macular degeneration OCT images. *Ophthalmology Retina, 3*(3), 211-215. https://doi.org/10.1016/j.oret.2018.08.002

12. Li, Z., He, Y., Keel, S., Meng, W., Chang, R. T., & He, M. (2020). Efficacy of a deep learning system for detecting diabetic retinopathy in retinal images from the general population. *JAMA Ophthalmology, 138*(4), 351-358. https://doi.org/10.1001/jamaophthalmol.2019.5474
13. Mookiah, M. R. K., Acharya, U. R., Lim, C. M., Ng, E. Y. K., & Suri, J. S. (2021). Application of deep learning to automated detection of diabetic retinopathy: A comprehensive review. *Computers in Biology and Medicine, 134*, 104452. https://doi.org/10.1016/j.compbiomed.2021.104452
14. Pascolini, D., & Mariotti, S. P. (2012). Global estimates of visual impairment: 2010. *British Journal of Ophthalmology, 96*(5), 614-618. https://doi.org/10.1136/bjophthalmol-2011-300539
15. Rajkomar, A., Dean, J., & Kohane, I. (2018). Machine learning in medicine. *The New England Journal of Medicine, 380*(14), 1347-1358. https://doi.org/10.1056/NEJMra1814259
16. Rajalakshmi, R., Subashini, R., Anjana, R. M., Mohan, V., & Deepa, M. (2018). Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. *Eye, 32*(6), 1138-1144. https://doi.org/10.1038/s41433-018-0029-y
17. Samek, W., Wiegand, T., & Müller, K.-R. (2017). Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. *arXiv preprint* arXiv:1708.08296. https://arxiv.org/abs/1708.08296
18. Scanlon, P. H. (2017). The English national screening programme for diabetic retinopathy 2003–2016. *Acta Diabetologica, 54*(6), 515-525. https://doi.org/10.1007/s00592-017-0970-3
19. Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., ... & Gardiner, T. A. (2016). The progress in understanding and treatment of diabetic retinopathy. *Progress in Retinal and Eye Research, 51*, 156-186. https://doi.org/10.1016/j.preteyeres.2015.11.001
20. Tan, G. S., Cheung, C. M. G., Sabanayagam, C., & Wong, T. Y. (2017). Strategies to optimize screening for diabetic retinopathy in Asia. *Asia-Pacific Journal of Ophthalmology, 6*(3), 269-276. https://doi.org/10.1097/APO.0000000000000163
21. Ting, D. S. W., Pasquale, L. R., Peng, L., Campbell, J. P., Lee, A. Y., Raman, R., … Wong, T. Y. (2019). Artificial intelligence and deep learning in ophthalmology. *British Journal of Ophthalmology, 103*(2), 167-175. https://doi.org/10.1136/bjophthalmol-2018-313173
22. Wong, T. Y., Sun, J., Kawasaki, R., Ruamviboonsuk, P., Gupta, N., Lansingh, V. C., ... & Yau, J. W. Y. (2018). Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. *Ophthalmology, 125*(10), 1608-1622. https://doi.org/10.1016/j.ophtha.2018.05.012
23. Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., … Wong, T. Y. (2012). Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care, 35*(3), 556-564. https://doi.org/10.2337/dc11-1909
24. Zhao, Y., Wong, T. Y., & Wang, J. J. (2019). Diabetic retinopathy and health disparities: implications for clinical practice and research. *Ophthalmic Epidemiology, 26*(4), 273-279. https://doi.org/10.1080/09286586.2018.1542159